Top 300 Pharmacy Drug Cards


Class: Hypolipidemic, Bile Acid Sequestrant

Dosage Forms. Tablet: 625 mg; Granules for Suspension: 3.75 g/packet


Common FDA Label Indication, Dosing, and Titration.

1. Primary hyperlipidemia: 1875 mg (3 tablets or 1.875 g powder packet) po bid or 3750 mg (6 tablets or 3.75 g powder packet) po daily

Off-Label Uses.

1. Familial hypercholesterolemia: 1875 mg (3 tablets or 1.875 g powder packet) po bid or 3750 mg (6 tablets or 3.75 g powder packet) po daily

MOA. Colesevelam is a nonabsorbed, polymeric, lipid-lowering agent that binds intestinal bile acids, resulting in the increased clearance of LDL-cholesterol and a reduction of total cholesterol. Unlike cholestyramine and colestipol, colesevelam is not an anion exchange resin but binds bile acids and impedes their reabsorption.

Drug Characteristics: Colesevelam


Medication Safety Issues: Colesevelam


Drug Interactions: Colesevelam


Adverse Reactions: Colesevelam


Efficacy Monitoring Parameters. Reduction in total cholesterol, LDL-cholesterol, and triglycerides levels; increase in HDL-cholesterol levels.

Toxicity Monitoring Parameters. Signs/symptoms of gastrointestinal side effects, vitamin A, D, E, or K deficiencies.

Key Patient Counseling Points. Should be used together with diet and exercise to lower cholesterol levels. Empty contents of powder packet into a glass and mix with 4-8 ounces of water; stir well and drink. Oral suspension should not be taken in its dry form. Take with a meal. Tablet should be swallowed with liquid (water, milk, or juice). May be dosed concomitantly with an HMG-CoA reductase inhibitor.

Clinical Pearls. Safety and efficacy not established in pediatric patients younger than 10 y of age or in premenarcheal girls. Patients with difficulty swallowing should use oral suspension instead of tablets.

If you find an error or have any questions, please email us at Thank you!